Physicians' Academy for Cardiovascular Education

Heart Failure

Follow the news, literature, and elearning on new developments in the management of Heart Failure.

Effects of iron deficiency on outcomes in HF

10' education - Apr. 6, 2021 - Adrian F. Hernandez, MD

Two medical therapies elevated to front line in 2021 update HF ECDP

5' education - Feb. 1, 2021 - Prof. James Januzzi, MD

Clinical outcome trial with IV iron in patients with iron deficiency, stabilized after acute HF

3' education - Dec. 15, 2020 - Prof. Peter van der Meer, MD, PhD

Ferric carboxymaltose in patients with iron deficiency after acute HF to reduce HF hospitalizations

5' education - Nov. 23, 2020 - Prof. Piotr Ponikowski, MD, PhD

The six pillars of therapy in HFrEF

3' education - Nov. 15, 2020 - Prof. Marc Pfeffer, MD, PhD

Introduction: Optimizing RAASi treatment through long-term potassium control

10' education - Oct. 22, 2020 - Prof. Peter van der Meer, MD

Novel potassium binders to improve management of chronic HF

10' education - Oct. 21, 2020 - Prof. Javed Butler, MD

Understanding risk of hyperkalemia in heart failure

10' education - Oct. 8, 2020 - Prof. Piotr Ponikowski, MD, PhD

Heart failure, a multimorbid syndrome: An increasing challenge to manage

10' education - Sep. 21, 2020 - Prof. Carolyn Lam, MD, PhD

New potassium binders for management of hyperkalemia in HF

10' education - Sep. 16, 2020 - Prof. Faiez Zannad, MD

Setting a patient on the right track following hospitalization for ADHF

15' education - Sep. 14, 2020 - Alexander Cadenbach, MD and prof. Mark Petrie, MD - Online CME

Iron deficiency in patients with heart failure

10' education - Sep. 8, 2020 - Niels Grote Beverborg, MD, PhD

Incredible consistency between two SGLT2i trials in HFrEF

3' education - Sep. 7, 2020 - Milton Packer, MD

How to diagnose and treat amyloidosis?

10' education - Sep. 1, 2020 - Prof. Peter van der Meer, MD, PhD

SGLT2 inhibitors: a new foundation in heart failure or another diuretic?

10' education - Sep. 1, 2020 - Prof. Rudolf de Boer, MD, PhD

Succes with SGLT2 inhibitor in HFrEF for all three end points

3' education - Aug. 29, 2020 - Milton Packer, MD

Remarkably similar findings with another SGLT2i in HFrEF

3' education - Aug. 29, 2020 - Prof. John McMurray

How will outcomes of ARNI trials impact diagnosis and management of HF?

10' education - Aug. 26, 2020 - Prof. Mark Petrie, MD

3rd Groningen Heart failure symposium: How to implement the newest HF therapies?

10' education - Aug. 25, 2020 - Prof. Dirk Jan van Veldhuisen, MD and prof. Adriaan Voors, MD

Getting better at diagnosing HFpEF - sharing clinical practice experience

15' education - July 28, 2020 - Prof. Mark Petrie, MD and Pardeep Jhund, MD, PhD - Online CME

Improving outcomes for patients following an admission with ADHF

15' education - July 7, 2020 - Prof. Mark Petrie, MD and Klaus Witte, MD - Online CME

Diabetes and CKD: is it all about managing glucose?

10' education - July 1, 2020 - Prof. Melanie Davies, MD
Lecture 1 out of 3

COVID-19, ACE2 and RAASi - a scientific perspective

10' education - Apr. 19, 2020 - Prof. Jan Danser, PhD
Lecture 2 out of 3

A clinical perspective on COVID-19, ACE2 and RAAS inhibition

10' education - Apr. 18, 2020 - Prof. Murray Epstein, MD
Lecture (panel discussion) 3 out of 3

COVID-19, ACE2 and RAAS inhibition: What are the implications for practice?

10' education - Apr. 17, 2020 - Profs. John Deanfield, Jan Danser and Murray Epstein

Use of ARNI in HFpEF patients reduces NT-proBNP levels

3' education - Apr. 8, 2020 - Jonathan Cunningham, MD

Added value of sGC stimulator in worsening HFrEF patients

3' education - Mar. 31, 2020 - Prof. Paul Armstrong, MD - ACC 2020

HFpEF: A misunderstood disease in search of a therapy

10' education - Jan. 23, 2020 - Prof. Scott Solomon

Effects of ARNI treatment on arterial hemodynamics, cardiac remodelling and pulmonary artery pressure in HFrEF

5' education - Jan. 14, 2020 - Akshay S. Desai, MD

Heart failure with mid-range ejection fraction

10' education - Jan. 6, 2020 - Prof. Burkert Pieske, MD

Effects of iron deficiency on outcomes in HF

10' education - Apr. 6, 2021 - Adrian F. Hernandez, MD
Adrian Hernandez gives background information about iron metabolism and discusses results from outcome trials on iron deficiency in HF.

Adrian Hernandez gives background information about iron metabolism and discusses results from outcome trials on iron deficiency in HF.

Ambient air pollution associated with increased risk of incident HF

Literature - Mar. 15, 2021 - Wang M et al. - Eur Heart J. 2021

This study introduced an air pollution score to investigate the association between long-term joint exposure to various ambient air pollutants and risk of incident HF in the UK Biobank.

Efficacy of two SGLT2i on CV and kidney outcomes in HFrEF according to kidney function

Literature - Feb. 25, 2021 - Jhund PS et al. and Zannad F et al., - Circulation. 2021

Subgroup analyses from DAPA-HF and EMPEROR-Reduced evaluated the effects of dapagliflozin and empagliflozin on CV and kidney outcomes according to baseline kidney function in patients with HFrEF.

SGLT2i reduces new-onset T2DM in patients with HFrEF

Literature - Feb. 18, 2021 - Inzucchi SE et al., - Diabetes Care. 2021

This exploratory analysis from DAPA-HF showed that dapagliflozin, compared to placebo, reduced new-onset T2DM in patients with HFrEF without diabetes at baseline.

FDA expands indication for ARNI in chronic HF

News - Feb. 17, 2021

The FDA has granted expansion of the label of sacubitril/valsartan for the treatment of patients with chronic HF, including both HFrEF and HFpEF. The label includes the statement that clinical judgment should be used in deciding whom to treat.

Proposed new algorithm for sequencing drug treatments for HFrEF

Literature - Feb. 15, 2021 - McMurray JJV and Packer M, - Circulation. 2020
John McMurray and Milton Packer proposed a new algorithm to achieve treatment with a beta-blocker, SGLT2i, ARNI and MRA within 4 weeks in patients with HFrEF.

John McMurray and Milton Packer proposed a new algorithm to achieve treatment with a beta-blocker, SGLT2i, ARNI and MRA within 4 weeks in patients with HFrEF.

CV and kidney outcomes with ARNI in HFpEF independent of MRA background use

Literature - Feb. 11, 2021 - Jering KS, et al. - JACC Heart Fail. 2021

This subanalysis of PARAGON-HF showed that efficacy outcomes with sacubitril/valsartan compared to valsartan were independent of MRA use in patients with HFpEF.

Simple biomarker-based risk score for prediction of incident HF in (pre-)diabetes

Literature - Feb. 2, 2021 - Pandey A et al., - JACC Heart Fail. 2020

A risk score based on elevated levels of hs-cTnT, NT-proBNP, and hs-CRP, and presence of left ventricular hypertrophy can stratify incident HF risk in patients with dysglycemia without CVD.

ARNI therapy does not affect CV reduction by SGLT2i in HFrEF

Literature - Feb. 2, 2021 - Packer M et al., - Eur Heart J. 2021

A subanalysis of EMPEROR-Reduced demonstrated that sacubitril/valsartan treatment in patients with HFrEF did not affect risk reducing effects of empagliflozin on HF and kidney events.

Two medical therapies elevated to front line in 2021 update HF ECDP

5' education - Feb. 1, 2021 - Prof. James Januzzi, MD
The 2021 update to the 2017 heart failure ECDP was just published. Prof. Januzzi explains the contribution of this document in addition to the guidelines and shares the most important updates.

The 2021 update to the 2017 heart failure ECDP was just published. Prof. Januzzi explains the contribution of this document in addition to the guidelines and shares the most important updates.

FDA approves sGC stimulator for treatment of HFrEF patients

News - Jan. 28, 2021

The soluble guanylate cyclase (sGC) stimulator vericiguat has been approved by the FDA to reduce risk of CV death and HF hospitalization following hospitalization for HF or need for outpatient IV diuretics in HFrEF patients.

2021 Update to the 2017 ACC ECDP for optimization HFrEF treatment

News - Jan. 19, 2021

The ACC Expert Consensus Decision Pathway (ECDP) for optimization of HFrEF treatment provides practical guidance for physicians in managing patients with HFrEF. The 2017 ECDP has now been updated.